Amlitelimab  (Synonyms: KY1005; SAR445229)

Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis^[1][2][3].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Amlitelimab (150 μg/mL) inhibits proliferation of human CD3 T cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Liquid

Colorless to light yellow

[Amlitelimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized Human OX40 Ligand/TNFSF4 Protein (ECD, mFc Tag) can bind Amlitelimab. The EC₅₀ for this effect is 3.87 ng/mL.
• 
  Loaded Amlitelimab on AHC2 biosensor, can bind OX40 Ligand/TNFSF4 (HEK293, His, HY-P70622) with an affinity constant of <1.000E-11 M as determined in BLI assay.

• [1]. Ana Maria Lé, et al. OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics 2022, 14(12), 2753.

  [2]. Saghari M, et al. OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005. Clin Pharmacol Ther. 2022 May;111(5):1121-1132.  [Content Brief]

  [3]. Tkachev V, et al. Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med. 2017 Sep 20;9(408):eaan3085.  [Content Brief]